National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

The Cost-effectiveness of Denosumab (Prolia®) for the Prevention of Osteoporotic Fractures in Postmenopausal Women.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/05/2010 July 2010 Reimbursement Recommended.

We consider denosumab a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish healthcare setting.

Denosumab (Prolia®) Summary